Screening for aggressive prostate cancer

Our approach

Prostate cancer is the most common cancer in men globally. Early detection is key to successful treatment.

Read more

Press releases

Pioneering screening test offers potential to find more aggressive prostate cancers

Newly elected Chairman Christopher O’Connell and CEO Martin Steinberg to lead the next phase of growth for A3P

Landmark Stockholm3 study highlighted as Editor’s Choice in European Urology

Independent Stockholm3 screening study selected as Best Oncology Abstract at EAU26

Stockholm3 screening detects aggressive and potentially lethal prostate cancers missed by current PSA thresholds

Stockholm3 included in NCCN guidelines for Prostate Cancer Early Detection

All Press releases